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1. ~trod~tio~ 
Heterogeneity of peptide hormones revealed by 
radioimmunoassay (RIA) has been demonstrated for 
a variety of peptides [ I,2 ] including human growth 
hormone (hGH) 13-51. Thus, two or three immuno- 
reactive components of hGH, ‘big-big’, ‘big’ and ‘little’ 
hGH were shown to be present in the blood [S] . Human 
prolactin (hPRL) is known to be related st~cturally 
to hGH though it has different immunoreactivity. 
Heterogeneity of serum hPRL has been demonstrated 
using electrophoresis [6] and gel chromatography [7] . 
In order to investigate the molecular heterogeneity of 
hPRL we have subjected serum with high hPRL-levels 
from patients with prolactin producing pituitary 
tumors to dextran gel chromatography. 
2. Materials and methods 
Human prolactin was measured by double-antibody- 
radioimmunoassay (RIA) using the VLS-kit [8] supplied 
by the National Pituitary Agency. Immunoreactive 
hPRL was expressed in /&J using the hPRL-7 l/222 
from the Medical Research Council, London, as 
reference preparation. The VLS-hPRL was labelled 
with lz51 according to Hunter and Greenwood [9] and 
the labelled protein purified on a Sephadex G-75 column 
(fig. 1). 
The coefficient of variation of the hPRL-RIA from 
day to day was 9.1%, the lowest detectable (Bo-3 
SD) hPRL-concentration 10 #J/ml. The hPRL-levels 
in normal females ranged from 100 to 650 @/ml. 
Dextran gel filtration was performed at room tempera- 
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Fig. 1. Chromatography of l’SI-labelled VLS-hPRL on 
Sephadex GSO. Fractions of 1 ml were collected (upper right). 
The fractions 7-10 were refiltrated on Sephadex G-75 and 
) fraction of the Sephadex G-75 eluate 
(0.8 KI,) was used as tracer in the hPRL-radioimmunoassay. 
ture with Sephadex G-75 using 0.05 M phospllate 
buffer, pH 7.5 with 0.1% sodium azide. The column 
(3 X 110 cm) was saturated with albumin before each 
chromatography and fractions of 5 ml were collected 
in which hPRL was measured. V~-hPRL-standard, 
pooled serum from pregnant females at term and 
serum from a female and a male patient with 
excessively high hPRL-levels were subjected to dextran 
gel tiltration. The male patient’s serum was chromato- 
graphed before and, after partial hypophysectomy by 
transsphenoidal approach lowering the hPRL from 
200 000 to 80 000 pU/ml. The serum samples were 
kept frozen at -18°C and thawed prior to chromato- 
graphy. 
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3. Results 
Chromatography of ’ 25 I-labelled VLS-hPRL 
revealed three radioactive peaks (fig. 1). The first peak 
eluted with the void volume and was bound by the 
antibody but no inhibition curve with increasing 
concentrations of hPRL-standard could be obtained. 
The second peak eluting at K, 0.4 showed no binding 
to the antibody whereas the third peak at E;D 0.75- 
0.8 bound to the antibody with satisfactory inhibition 
curves representing the labelled hPRL. Unlabelled 
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immunoreactive VLS-hPRL showed marked hetero- 
geneity (fig. 2) and immunoreactive hPRL of pregnancy 
serum eluted with a minor peak at K, 0.4 and a Large 
peak at KD 0.75-0.8 (fig. 2). 
Chromatography of serum from patients with hPRL 
producing pituitary tumors and very high hPRL-levels 
showed consistently two immunoreactive hPRL 
components, a ‘big’ hPRL with an approximate MW 
44 000 representing 23-24% and a ‘little’ hPRL 
representing 76-77% of the total hPRL-immuno- 
reactivity (fig. 3). These two components had identical 
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Fig. 2. Dextxan gel titration of uniabelled VLS-hPRL and 
pooled pregnancy serum. Two minor fractions of the VLS 
preparation eluted with the void volume (3%) and at KD 
0.4 (1.5%), the main peak (82%) at KD 0.8 representing the 
regular or ‘little’ hPRL with mol. wt. 22 000. Pregnancy 
serum showed a ‘big’ hPRL component at KD 0.4 (8%) and 
a ‘little’ component at KD 0.75-08. 
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Fig. 3. Dextran gel filtration of sera with high hPRL-levels. 
The upper figure shows the elution pattern of the hPRL- 
immunoreactivity of one female patient with a hPRL-pro- 
ducing pituitary adenoma. A similar pattern is demonstrated 
in a male patient with byperprolactinem~ and pituitary tumor 
(middle), which did not change after lowering the hPRL-level 
by partial removal of the pituitary adenoma (below). 
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Fig. 4. Rechromatography of ‘big’ and ‘little’ hPRLserum com- 
ponents. No conversion of ‘big’ into ‘little’ or vice versa could 
be detected. 
immunoreactivity as could be demonstrated in the 
RIA by supe~mposable d~ution curves. 
After rechromatography ‘big’ hPRL eluted as ‘big’ 
and ‘little’ as ‘little’ hPRL (fig. 4) even when the 
samples were kept frozen prior to chromatography 
over several days. 
4. Discussion 
It has been demonstrated for most peptide hormones 
that the immunoreacti~ty can reside in more than one 
molecular size [ 1,2] . These multiple immunoreactive 
components have been shown to be present in their 
glands of origin and in the circulation. Turkington has 
described two forms of serum hPRL which could be 
separated by electrophoretic mobility into ‘fast’ and 
‘slow’ moving hPRL [6] . Recently Rogol and Rosen 
[7] reported a ‘large’ hPRL as a major component in 
the plasma of a patient with acromegaly and elevated 
hPRL-levels which could be separated by Sephadex 
G-l 00 from regular hPRL. Our dextran gel studies 
show also two components of circulating immuno- 
reactive hPRL. The molecular weight of ‘big’ hPRL 
according to the Kc, can be estimated to be approxima- 
tely 44 000 similar to the large hPRL described by 
Rogol and Rosen [7]. The ‘big’ hPRL represents 23 
to 24% of total hPRL-immunoreactivity and does not 
correlate to the absolute hPRL concentration in the 
serum (fig. 3). Less ‘big’ hPRL was found in pregnancy 
serum. This might be attributed to the sensitivity of 
the hPRL-RIA (10 yU 71/222/ml= 0.5 ng VLS/ml) 
which does not allow to detect the total ‘big’ hPRL- 
fraction, ‘Little’ hPRL elutes at K, 0.75 to 0.8 
corresponding to mol. wt. 22 000. No conversion of 
‘big’ into ‘little’ hPRL could be demonstrated by 
reflltration of the hPRL components, which excludes 
‘big’ hPRL being an artifact as has been tentatively 
suggested [7]. 
These findings are similar to what has been shown 
for human growth hormone [ 51 another single chain 
pituitary peptide chemically related to hPRL. How 
these components relate to the hPRL fractions described 
by Turkington [6] is open. Further investigation has 
to clarify wether ‘big’ hPRL represents a hPRL- 
precursor, a dimer or is due to protein binding as well 
as its possible physiologic significance. 
Supported by the Deutsche Forschungsgemein~haft, 
SFB 5 1. VLS-hPRL-RIA-kits were obtained from 
the National Pituitary Agency, NIAMDD, Bethesda, 
Md., the hPRL-71/222 from the Medical Research 
Council, London. 
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